A patient who is diagnosed with genital herpes is using topical acyclovir, and the nurse is providing instructions about adverse effects. What topic will the nurse include?

Choice A reason: Levofloxacin, a fluoroquinolone, is associated with tendonitis and tendon rupture, particularly in older adults. It disrupts collagen synthesis, weakening tendons like the Achilles, especially in patients over 60 or on corticosteroids. Monitoring for tendon pain is critical to prevent debilitating injury during therapy.

Choice B reason: Hypotension and tachycardia are not primary adverse effects of levofloxacin. Fluoroquinolones may cause QT prolongation, but cardiovascular effects are rare. Their main toxicities include tendon damage and CNS effects, making this an incorrect choice for monitoring in this patient.

Choice C reason: Double vision and floaters are not typical levofloxacin side effects. Fluoroquinolones may cause CNS effects like dizziness or confusion, but visual disturbances like these are more associated with drugs like chloroquine. Tendon issues are a more significant concern with levofloxacin.

Choice D reason: Numbness and tingling are not common with levofloxacin. While fluoroquinolones can cause CNS side effects like seizures in rare cases, peripheral neuropathy is less frequent. Tendonitis and rupture are more prominent risks, especially in older patients, making this an incorrect monitoring priority.

Choice A reason: Stopping antitubercular medication due to dark orange urine is incorrect, as this is an expected effect of rifampin. Discontinuing therapy prematurely risks treatment failure and resistance development. Patient education about harmless discoloration is needed, not cessation, unless serious adverse effects like hepatotoxicity occur.

Choice B reason: Dark orange urine does not indicate worsening tuberculosis. It is a benign effect of rifampin’s red-orange metabolite excreted in urine. Worsening tuberculosis would present with increased symptoms like cough or fever, not urine discoloration, making this response inaccurate and alarming to the patient.

Choice C reason: Dark orange urine is a common, expected effect of rifampin, not an unusual finding requiring clinic evaluation. Rifampin’s metabolites cause harmless discoloration of bodily fluids. Only symptoms like jaundice or abdominal pain would warrant further investigation, not this benign side effect.

Choice D reason: Dark orange urine is an expected side effect of rifampin, a first-line antitubercular drug. Its red-orange metabolite discolors urine, sweat, and tears, which is harmless. Educating the patient about this effect reassures them, ensures adherence, and prevents unnecessary concern, focusing on other potential serious side effects.